SpringerLink
Log in

Lung Cancer Screening

  • Chapter
  • First Online:
Lung Cancer

Part of the book series: Respiratory Medicine ((RM))

  • 444 Accesses

Abstract

For decades, lung cancer screening trials failed to show a mortality benefit until the US-based National Lung Screening Trial was published in 2011. Since then, more evidence has reinforced the benefit of lung cancer screening with low-dose chest computed tomography. However, implementation has been very slow due to unprecedented requirements for conducting lung cancer screening. We review the history of lung screening, approaches to patient selection, procedures for conducting and interpreting low-dose chest computed tomography, and challenges in implementing screening.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
GBP 19.95
Price includes VAT (United Kingdom)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
GBP 95.50
Price includes VAT (United Kingdom)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
GBP 119.99
Price includes VAT (United Kingdom)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Sharma D, Newman TG, Aronow WS. Lung cancer screening: history, current perspectives, and future directions. Arch Med Sci. 2015;11(5):1033–43.

    PubMed  PubMed Central  Google Scholar 

  2. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. Br Med J. 1950;2(4682):739–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Interv Radiol. 2013;30(2):93–8.

    Article  Google Scholar 

  4. Weiss W, Boucot KR, Cooper DA. The Philadelphia pulmonary neoplasm research project. Survival factors in bronchogenic carcinoma. JAMA. 1971;216(13):2119–23.

    Article  CAS  PubMed  Google Scholar 

  5. Berlin NI, Buncher CR, Fontana RS, Frost JK, Melamed MR. The National Cancer Institute Cooperative Early Lung Cancer Detection Program. Results of the initial screen (prevalence). Early lung cancer detection: introduction. Am Rev Respir Dis. 1984;130(4):545–9.

    CAS  PubMed  Google Scholar 

  6. Oken MM, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011;306(17):1865–73.

    Article  CAS  PubMed  Google Scholar 

  7. United States Preventive Services Task Force. Final recommendation statement lung cancer: screening, May 2004: United States Preventive Services Task Force; 2004. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening-2004. Accessed 8 Sep 2022.

  8. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.

    Article  PubMed  Google Scholar 

  9. United States Preventive Services Task Force. Final recommendation statement lung cancer screening: United States Preventative Services Task Force. 2013. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening-december-2013. Accessed 8 Sep 2022.

  10. de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160(5):311–20.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gates TJ. Screening for cancer: concepts and controversies. Am Fam Physician. 2014;90(9):625–31.

    PubMed  Google Scholar 

  12. Bazemore A, Wilkinson E, Petterson S, Green LA. Proportional erosion of the primary care physician workforce has continued since 2010. Am Fam Physician. 2019;100(4):211–2.

    PubMed  Google Scholar 

  13. Seiler N, Malcarney MB, Horton K, Dafflitto S. Coverage of clinical preventive services under the Affordable Care Act: from law to access. Public Health Rep. 2014;129(6):526–32.

    Article  PubMed  PubMed Central  Google Scholar 

  14. United States Preventive Services Task Force. Procedure manual Appendix I. Congressional mandate establishing the U.S. Preventive Services Task Force. 2019. https://uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-appendix-i. Accessed 28 Feb 2022.

  15. Centers for Medicare & Medicaid Services. National coverage analysis; Tracking sheet; Screening for lung cancer with low dose computed tomography (LDCT) CAG-00439N. 2015. https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?NCAId=274&bc=AiAAAAAAAgAAAA%3d%3d&. Accessed 17 Aug 2022.

  16. Centers for Medicare & Medicaid Services. National coverage analysis; Decision memo; Screening for lung cancer with low dose computed tomography (LDCT) CAG-00439N. 2015. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=274&bc=0. Accessed 30 Aug 2022.

  17. de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen R, Choi SE, Miller M, Moolgavkar S, Pinsky PF, Berg CD, de Gonzalez AB, Black WC, Tammemagi CM, Hazelton WD, Feuer EJ, McMahon PM. Benefits and harms of computed tomography lung cancer screening programs for high-risk populations. Rockville, MD: Agency for Healthcare Research and Quality; 2013. Contract No.: AHRQ Publication 13-05196-EF-2.

    Google Scholar 

  18. Becker N, Motsch E, Trotter A, Heussel CP, Dienemann H, Schnabel PA, et al. Lung cancer mortality reduction by LDCT screening-results from the randomized German LUSI trial. Int J Cancer. 2020;146(6):1503–13.

    Article  CAS  PubMed  Google Scholar 

  19. Wille MM, Dirksen A, Ashraf H, Saghir Z, Bach KS, Brodersen J, et al. Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 2016;193(5):542–51.

    Article  CAS  PubMed  Google Scholar 

  20. Pastorino U, Rossi M, Rosato V, Marchianò A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308–15.

    Article  PubMed  Google Scholar 

  21. Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax. 2011;66(4):308–13.

    Article  CAS  PubMed  Google Scholar 

  22. Silva M, Pastorino U, Sverzellati N. Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials. Clin Radiol. 2017;72(5):389–400.

    Article  CAS  PubMed  Google Scholar 

  23. van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: latest developments and unanswered questions. Lancet Respir Med. 2016;4(9):749–61.

    Article  PubMed  Google Scholar 

  24. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–13.

    Article  PubMed  Google Scholar 

  25. van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120(4):868–74.

    Article  PubMed  Google Scholar 

  26. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, et al. Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst. 2010;102(23):1771–9.

    Article  Google Scholar 

  27. Majeed H, Zhu H, Williams SA, Hamann HA, Natchimuthu VS, Lee J, et al. Prevalence and impact of medical comorbidities in a real-world lung cancer screening population. Clin Lung Cancer. 2022;23(5):419–27.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Melzer AC, Begnaud A, Lindgren BR, Schertz K, Fu SS, Vock DM, et al. Self-reported exercise capacity among current smokers eligible for lung cancer screening: distribution and association with key comorbidities. Cancer Treat Res Commun. 2021;28:100443.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP, et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Screening for lung cancer with low-dose computed tomography: an evidence review for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality (US); 2021.

    Google Scholar 

  30. Guichet PL, Liu BY, Desai B, Surani Z, Cen SY, Lee C. Preliminary results of lung cancer screening in a socioeconomically disadvantaged population. AJR Am J Roentgenol. 2018;210(3):489–96.

    Article  PubMed  Google Scholar 

  31. Prosper AE, Inoue K, Brown K, Bui AAT, Aberle D, Hsu W. Association of inclusion of more black individuals in lung cancer screening with reduced mortality. JAMA Netw Open. 2021;4(8):e2119629.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Aldrich MC, Mercaldo SF, Sandler KL, Blot WJ, Grogan EL, Blume JD. Evaluation of USPSTF lung cancer screening guidelines among African American adult smokers. JAMA Oncol. 2019;5(9):1318–24.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Haddad DN, Sandler KL, Henderson LM, Rivera MP, Aldrich MC. Disparities in lung cancer screening: a review. Ann Am Thorac Soc. 2020;17(4):399–405.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

    Article  PubMed  Google Scholar 

  35. National Lung Screening Trial Research T, Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, et al. The National Lung Screening Trial: overview and study design. Radiology. 2011;258(1):243–53.

    Article  Google Scholar 

  36. Ru Zhao Y, **e X, de Koning HJ, Mali WP, Vliegenthart R, Oudkerk M. NELSON lung cancer screening study. Cancer Imaging. 2011;11 Spec No A(1A):S79–84.

    Article  Google Scholar 

  37. Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP, et al. Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(10):971–87.

    Article  PubMed  Google Scholar 

  38. Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, et al. Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force. JAMA. 2021;325(10):988–97.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Centers for Medicare & Medicaid Services. National coverage analysis; Tracking sheet; Screening for lung cancer with low dose computed tomography (LDCT) CAG-00439R. 2022. https://www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?ncaid=304. Accessed 17 Aug 2022.

  40. Centers for Medicare & Medicaid Services. National coverage analysis; Decision memo; Screening for lung cancer with low dose computed tomography (LDCT) CAG-00439R. 2022. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=304. Accessed 28 Feb 2022.

  41. National Comprehensive Cancer Network. NCCN guidelines version 2.2022 lung cancer screening 2022. 2022. https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. Accessed 2 Aug 2022.

  42. American College of Radiology. Adult lung cancer screening technical specifications. https://www.acraccreditation.org/-/media/ACRAccreditation/Documents/LCS/Lung-Cancer-Screening-Technical-Specifications.pdf. Accessed 5 Jul 2022.

  43. American College of Radiology. ACR–STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT). 2019. https://www.acr.org/-/media/ACR/Files/Practice-Parameters/CT-LungCaScr.pdf. Accessed 5 Jul 2022.

  44. Vonder M, Dorrius MD, Vliegenthart R. Latest CT technologies in lung cancer screening: protocols and radiation dose reduction. Transl Lung Cancer Res. 2021;10(2):1154–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Chelala L, Hossain R, Kazerooni EA, Christensen JD, Dyer DS, White CS. Lung-RADS version 1.1: challenges and a look ahead, from the AJR special series on radiology reporting and data systems. AJR Am J Roentgenol. 2021;216(6):1411–22.

    Article  PubMed  Google Scholar 

  46. National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.

    Article  Google Scholar 

  47. American College of Radiology. Lung-RADS version 1.0. 2014.

    Google Scholar 

  48. Henschke CI, Yip R, Yankelevitz DF, Smith JP. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. Ann Intern Med. 2013;158(4):246–52.

    Article  PubMed  Google Scholar 

  49. McKee BJ, Regis SM, McKee AB, Flacke S, Wald C. Performance of ACR lung-RADS in a clinical CT lung screening program. J Am Coll Radiol. 2015;12(3):273–6.

    Article  PubMed  Google Scholar 

  50. Pinsky PF, Gierada DS, Black W, Munden R, Nath H, Aberle D, et al. Performance of lung-RADS in the national lung screening trial: a retrospective assessment. Ann Intern Med. 2015;162(7):485–91.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Dyer SC, Bartholmai BJ, Koo CW. Implications of the updated lung CT screening reporting and data system (lung-RADS version 1.1) for lung cancer screening. J Thorac Dis. 2020;12(11):6966–77.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Devaraj A, van Ginneken B, Nair A, Baldwin D. Use of volumetry for lung nodule management: theory and practice. Radiology. 2017;284(3):630–44.

    Article  PubMed  Google Scholar 

  53. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage grou**s in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.

    Article  PubMed  Google Scholar 

  54. Paci E, Puliti D, Lopes Pegna A, Carrozzi L, Picozzi G, Falaschi F, et al. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax. 2017;72(9):825–31.

    Article  PubMed  Google Scholar 

  55. Infante M, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med. 2009;180(5):445–53.

    Article  PubMed  Google Scholar 

  56. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax. 2012;67(4):296–301.

    Article  PubMed  Google Scholar 

  57. Pastorino U, Rossi M, Rosato V, Marchiano A, Sverzellati N, Morosi C, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21(3):308–15.

    Article  PubMed  Google Scholar 

  58. Flores R, Patel P, Alpert N, Pyenson B, Taioli E. Association of stage shift and population mortality among patients with non-small cell lung cancer. JAMA Netw Open. 2021;4(12):e2137508.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Szklo M, Neito FJ. Epidemiology beyond the basics. 2nd ed. Sudbury, MA: Jones and Bartlett Publishers; 2007.

    Google Scholar 

  60. Mazzone PJ, Silvestri GA, Souter LH, Caverly TJ, Kanne JP, Katki HA, et al. Screening for lung cancer: CHEST guideline and expert panel report. Chest. 2021;160(5):e427–e94.

    Article  PubMed  PubMed Central  Google Scholar 

  61. McCunney RJ, Li J. Radiation risks in lung cancer screening programs: a comparison with nuclear industry workers and atomic bomb survivors. Chest. 2014;145(3):618–24.

    Article  PubMed  Google Scholar 

  62. Nguyen XV, Davies L, Eastwood JD, Hoang JK. Extrapulmonary findings and malignancies in participants screened with chest CT in the national lung screening trial. J Am Coll Radiol. 2017;14(3):324–30.

    Article  PubMed  Google Scholar 

  63. Tanoue LT, Sather P, Cortopassi I, Dicks D, Curtis A, Michaud G, et al. Standardizing the reporting of incidental, non-lung cancer (category S) findings identified on lung cancer screening low-dose CT imaging. Chest. 2022;161(6):1697–706.

    Article  PubMed  Google Scholar 

  64. Pu CY, Lusk CM, Neslund-Dudas C, Gadgeel S, Soubani AO, Schwartz AG. Comparison between the 2021 USPSTF lung cancer screening criteria and other lung cancer screening criteria for racial disparity in eligibility. JAMA Oncol. 2022;8(3):374–82.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, et al. Risk prediction models for selection of lung cancer screening candidates: a retrospective validation study. PLoS Med. 2017;14(4):e1002277.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368(8):728–36.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Lim KP, Marshall H, Tammemägi M, Brims F, McWilliams A, Stone E, et al. Protocol and rationale for the international lung screening trial. Ann Am Thorac Soc. 2020;17(4):503–12.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Fedewa SA, Kazerooni EA, Studts JL, Smith RA, Bandi P, Sauer AG, et al. State variation in low-dose computed tomography scanning for lung cancer screening in the United States. J Natl Cancer Inst. 2021;113(8):1044–52.

    Article  PubMed  Google Scholar 

  69. Fedewa SA, Bandi P, Smith RA, Silvestri GA, Jemal A. Lung Cancer Screening Rates During the COVID-19 Pandemic. Chest. 2022;161(2):586–9.

    Article  CAS  PubMed  Google Scholar 

  70. National Cancer Institute. Cancer trends progress report; breast cancer screening: National Institutes of Health. 2022. https://progressreport.cancer.gov/detection/breast_cancer. Accessed 25 Jul 2022.

  71. National Cancer Institute. Cancer trends progress report; lung cancer screening. National Institutes of Health. 2022. https://progressreport.cancer.gov/detection/lung_cancer. Accessed 25 Jul 2022.

  72. Hendrick RE, Helvie MA. Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death. AJR Am J Roentgenol. 2012;198(3):723–8.

    Article  PubMed  Google Scholar 

  73. Tammemägi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, et al. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med. 2014;11(12):e1001764.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Tarabichi Y, Kats DJ, Kaelber DC, Thornton JD. The impact of fluctuations in pack-year smoking history in the electronic health record on lung cancer screening practices. Chest. 2018;153(2):575–8.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Coughlin JM, Zang Y, Terranella S, Alex G, Karush J, Geissen N, et al. Understanding barriers to lung cancer screening in primary care. J Thorac Dis. 2020;12(5):2536–44.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Centers for Medicare & Medicaid Services. National coverage determination mammograms 220.4. 1978. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=186. Accessed 26 Jul 2022.

  77. Wang GX, Baggett TP, Pandharipande PV, Park ER, Percac-Lima S, Shepard JO, et al. Barriers to lung cancer screening engagement from the patient and provider perspective. Radiology. 2019;290(2):278–87.

    Article  PubMed  Google Scholar 

  78. Carter-Harris L, Gould MK. Multilevel barriers to the successful implementation of lung cancer screening: why does it have to be so hard? Ann Am Thorac Soc. 2017;14(8):1261–5.

    Article  PubMed  Google Scholar 

  79. Melzer AC, Golden SE, Ono SS, Datta S, Crothers K, Slatore CG. What exactly is shared decision-making? A qualitative study of shared decision-making in lung cancer screening. J Gen Intern Med. 2020;35(2):546–53.

    Article  PubMed  Google Scholar 

  80. Eberth JM, Zgodic A, Pelland SC, Wang SY, Miller DP. Outcomes of shared decision-making for low-dose screening for lung cancer in an academic medical center. J Cancer Educ. 2022;38:522.

    Article  PubMed  Google Scholar 

  81. Brenner AT, Malo TL, Margolis M, Elston Lafata J, James S, Vu MB, et al. Evaluating Shared Decision Making for Lung Cancer Screening. JAMA Intern Med. 2018;178(10):1311–6.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Nishi SPE, Lowenstein LM, Mendoza TR, Lopez Olivo MA, Crocker LC, Sepucha K, et al. Shared decision-making for lung cancer screening: how well are we “sharing”? Chest. 2021;160(1):330–40.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Kaufman M, Schnure N, Nicholson A, Leone F, Guerra C. A lung cancer screening personalized decision-aid improves knowledge and reduces decisional conflict among a diverse population of smokers at an urban academic medical center. J Health Disparit Res Pract. 2020;13(2):3.

    Google Scholar 

  84. Volk RJ, Lowenstein LM, Leal VB, Escoto KH, Cantor SB, Munden RF, et al. Effect of a patient decision aid on lung cancer screening decision-making by persons who smoke: a randomized clinical trial. JAMA Netw Open. 2020;3(1):e1920362.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Tan NQP, Nishi SPE, Lowenstein LM, Mendoza TR, Lopez-Olivo MA, Crocker LC, et al. Impact of the shared decision-making process on lung cancer screening decisions. Cancer Med. 2022;11(3):790–7.

    Article  PubMed  Google Scholar 

  86. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95(6):470–8.

    Article  PubMed  Google Scholar 

  87. Agency for Healthcare Research and Quality. Is lung cancer screening right for me? A decision aid for people considering lung cancer screening with low-dose computed tomography. 2016. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/lung-cancer-about-160226.pdf. Accessed 25 Aug 2022.

  88. Alishahi Tabriz A, Neslund-Dudas C, Turner K, Rivera MP, Reuland DS, Elston Lafata J. How health-care organizations implement shared decision-making when it is required for reimbursement: the case of lung cancer screening. Chest. 2021;159(1):413–25.

    Article  PubMed  Google Scholar 

  89. Sakoda LC, Rivera MP, Zhang J, Perera P, Laurent CA, Durham D, et al. Patterns and factors associated with adherence to lung cancer screening in diverse practice settings. JAMA Netw Open. 2021;4(4):e218559.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Smith HB, Ward R, Frazier C, Angotti J, Tanner NT. Guideline-recommended lung cancer screening adherence is superior with a centralized approach. Chest. 2022;161(3):818–25.

    Article  PubMed  Google Scholar 

  91. Hirsch EA, New ML, Brown SL, Barón AE, Sachs PB, Malkoski SP. Impact of a hybrid lung cancer screening model on patient outcomes and provider behavior. Clin Lung Cancer. 2020;21(6):e640–e6.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Lopez-Olivo MA, Maki KG, Choi NJ, Hoffman RM, Shih YT, Lowenstein LM, et al. Patient adherence to screening for lung cancer in the US: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(11):e2025102.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Kim RY, Rendle KA, Mitra N, Saia CA, Neslund-Dudas C, Greenlee RT, et al. Racial disparities in adherence to annual lung cancer screening and recommended follow-up care: a multicenter cohort study. Ann Am Thorac Soc. 2022;19(9):1561–9.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes Control. 2017;28(9):947–58.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Rivera MP, Durham DD, Long JM, Perera P, Lane L, Lamb D, et al. Receipt of recommended follow-up care after a positive lung cancer screening examination. JAMA Netw Open. 2022;5(11):e2240403.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Rivera MP, Katki HA, Tanner NT, Triplette M, Sakoda LC, Wiener RS, et al. Addressing disparities in lung cancer screening eligibility and healthcare access. An Official American Thoracic Society Statement. Am J Respir Crit Care Med. 2020;202(7):e95–e112.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Schiffelbein JE, Carluzzo KL, Hasson RM, Alford-Teaster JA, Imset I, Onega T. Barriers, facilitators, and suggested interventions for lung cancer screening among a rural screening-eligible population. J Prim Care Community Health. 2020;11:2150132720930544.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Niranjan SJ, Opoku-Agyeman W, Carroll NW, Dorsey A, Tipre M, Baskin ML, et al. Distribution and geographic accessibility of lung cancer screening centers in the United States. Ann Am Thorac Soc. 2021;18(9):1577–80.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Pistelli F, Aquilini F, Falaschi F, Puliti D, Ocello C, Lopes Pegna A, et al. Smoking cessation in the ITALUNG lung cancer screening: what does “Teachable Moment” mean? Nicotine Tob Res. 2020;22(9):1484–91.

    Article  PubMed  Google Scholar 

  100. Heiden BT, Engelhardt KE, Cao C, Meyers BF, Puri V, Cao Y, et al. Association between lung cancer screening and smoking cessation. Cancer Epidemiol. 2022;79:102194.

    Article  PubMed  Google Scholar 

  101. Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962–70.

    Article  PubMed  Google Scholar 

  102. Shen J, Crothers K, Kross EK, Petersen K, Melzer AC, Triplette M. Provision of smoking cessation resources in the context of in-person shared decision-making for lung cancer screening. Chest. 2021;160(2):765–75.

    Article  PubMed  Google Scholar 

  103. Lowenstein LM, Nishi SPE, Lopez-Olivo MA, Crocker LC, Choi N, Kim B, et al. Smoking cessation services and shared decision-making practices among lung cancer screening facilities: a cross-sectional study. Cancer. 2022;128(10):1967–75.

    Article  CAS  PubMed  Google Scholar 

  104. Joseph AM, Rothman AJ, Almirall D, Begnaud A, Chiles C, Cinciripini PM, et al. Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med. 2018;197(2):172–82.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, et al. Assessment of plasma proteomics biomarker’s ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial. Chest. 2018;154(3):491–500.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Schult TA, Lauer MJ, Berker Y, Cardoso MR, Vandergrift LA, Habbel P, et al. Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics. Proc Natl Acad Sci U S A. 2021;118(51):e2110633118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Feil C, Staib F, Berger MR, Stein T, Schmidtmann I, Forster A, et al. Sniffer dogs can identify lung cancer patients from breath and urine samples. BMC Cancer. 2021;21(1):917.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Meng S, Li Q, Zhou Z, Li H, Liu X, Pan S, et al. Assessment of an exhaled breath test using high-pressure photon ionization time-of-flight mass spectrometry to detect lung cancer. JAMA Netw Open. 2021;4(3):e213486.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e1S–e29S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Loewen G, Black B, McNew T, Miller A. Lung cancer screening in patients with Libby amphibole disease: high yield despite predominantly environmental and household exposure. Am J Ind Med. 2019;62(12):1112–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Markowitz SB, Manowitz A, Miller JA, Frederick JS, Onyekelu-Eze AC, Widman SA, et al. Yield of low-dose computerized tomography screening for lung cancer in high-risk workers: the case of 7189 US Nuclear Weapons Workers. Am J Public Health. 2018;108(10):1296–302.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 2020;158(1):406–15.

    Article  CAS  PubMed  Google Scholar 

  113. Davenport MS, Bruno MA, Iyer RS, Johnson AM, Herrera R, Nicola GN, et al. ACR statement on safe resumption of routine radiology care during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Radiol. 2020;17(7):839–44.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Van Haren RM, Delman AM, Turner KM, Waits B, Hemingway M, Shah SA, et al. Impact of the COVID-19 pandemic on lung cancer screening program and subsequent lung cancer. J Am Coll Surg. 2021;232(4):600–5.

    Article  PubMed  Google Scholar 

  115. Joung RH, Nelson H, Mullett TW, Kurtzman SH, Shafir S, Harris JB, et al. A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic. Cancer. 2022;128(11):2119–25.

    Article  CAS  PubMed  Google Scholar 

  116. Henderson LM, Benefield T, Bosemani T, Long JM, Rivera MP. Impact of the COVID-19 pandemic on volumes and disparities in lung cancer screening. Chest. 2021;160(1):379–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medicine, University of Minnesota Twin Cities, Minneapolis, MN, USA

    Christine M. Lambert & Abbie Begnaud

Authors
  1. Christine M. Lambert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abbie Begnaud
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abbie Begnaud .

Editor information

Editors and Affiliations

  1. Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA

    Christina R. MacRosty

  2. Division of Pulmonary and Critical Care Medicine, University of Rochester Medical Center, Rochester, NY, USA

    M. Patricia Rivera

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lambert, C.M., Begnaud, A. (2023). Lung Cancer Screening. In: MacRosty, C.R., Rivera, M.P. (eds) Lung Cancer. Respiratory Medicine. Humana, Cham. https://doi.org/10.1007/978-3-031-38412-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-38412-7_2

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-031-38411-0

  • Online ISBN: 978-3-031-38412-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation